CRISPR Therapeutics (CRSP) Earnings Date, Estimates & Call Transcripts $52.16 +0.49 (+0.94%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$52.16 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRISPR Therapeutics Earnings Summary CRISPR Therapeutics issued Q1 2025 earnings on May 6, 2025, reporting an EPS of -$1.58, which missed the consensus estimate of -$1.27 by $0.31. Its revenue was up 71.6% on a year-over-year basis. With a trailing EPS of -$4.52, CRISPR Therapeutics' earnings are expected to grow next year, from ($5.16) to ($4.03) per share. Upcoming Q2 Earnings DateAug. 4Before Market OpensEstimatedConsensus EPS (May. 6) -$1.27 Actual EPS (May. 6) -$1.58 Missed By -$0.31 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)CRSP Upcoming EarningsCRISPR Therapeutics' next earnings date is estimated for Monday, August 4, 2025, based on past reporting schedules. Powered by Get CRISPR Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCRSP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CRSP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. CRISPR Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20255-$1.60-$0.74-$1.17Q2 20255-$2.27-$0.93-$1.55Q3 20255-$1.55-$1.07-$1.28Q4 20255-$1.35-$1.03-$1.21 FY 2025 20 -$6.77 -$3.77 -$5.21 Q1 20263-$1.56-$0.93-$1.18Q2 20263-$1.59-$0.89-$1.15Q3 20263-$1.33-$0.76-$1.04Q4 20263-$1.18-$0.67-$0.93 FY 2026 12 -$5.66 -$3.25 -$4.31 Q1 20271-$1.47-$1.47-$1.47 CRISPR Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/4/2025(Estimated)--------5/6/2025Q1 2025-$1.27-$1.58 -$0.31-$1.58--2/11/2025Q4 2024-$1.15-$0.44+$0.71-$0.44--11/5/2024Q3 2024-$1.42-$1.01+$0.41-$1.01$6.65M$0.60M8/5/2024Q2 2024-$1.43-$1.49 -$0.06-$1.49$12.31M$0.52M5/8/2024Q1 2024-$1.35-$1.43 -$0.08-$1.43$25.53M$0.50M2/21/2024Q4 2023$0.15$1.10+$0.95$1.10$148.72M$201.20M11/6/2023Q3 2023-$2.04-$1.41+$0.63-$1.41$5.05M-8/7/2023Q2 2023-$2.13-$0.98+$1.15-$0.98$1.80M$70.00M CRISPR Therapeutics Earnings - Frequently Asked Questions When is CRISPR Therapeutics' earnings date? CRISPR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 4th, 2025 based off last year's report dates. Learn more on CRSP's earnings history. Did CRISPR Therapeutics beat their earnings estimates last quarter? In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) missed the analysts' consensus estimate of ($1.27) by $0.31 with a reported earnings per share (EPS) of ($1.58). Learn more on analysts' earnings estimate vs. CRSP's actual earnings. How much revenue does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $35 million. How much profit does CRISPR Therapeutics generate each year? CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of -$366.25 million. CRSP has generated -$4.52 earnings per share over the last four quarters. What is CRISPR Therapeutics' EPS forecast for next year? CRISPR Therapeutics' earnings are expected to grow from ($5.16) per share to ($4.03) per share in the next year. More Earnings Resources from MarketBeat Related Companies Allogene Therapeutics Earnings Date Axsome Therapeutics Earnings Date Beam Therapeutics Earnings Date Editas Medicine Earnings Date KALA BIO Earnings Date Moderna Earnings Date Intellia Therapeutics Earnings Date Vertex Pharmaceuticals Earnings Date Illumina Earnings Date Genmab A/S Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs This page (NASDAQ:CRSP) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
